Distribution September 26, 2018 Frequently Asked Questions – 340B Program 4 Minute Read The 340B program is subject to increasing scrutiny as pharmaceutical manufacturers search for solutions to identify and act on non-compliance such as diversion and duplicate discounts. This post is...
Managed Services July 27, 2018 The Economics of Rare Disease and Implications for Payer Contract Strategy 3 Minute Read Rare diseases affect 30 million people in the United States, which roughly equates to 10% of the population. In 2017, 40% of the novel drugs approved by the FDA...
